SCOPE 2019

Not there yet? With bad data, AI accelerates bad processes: SCOPE panelist

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/kishore kumar)
(Image: Getty/kishore kumar)

Related tags Artificial intelligence AI

Artificial intelligence works best in a standardized environment, say industry experts. Workflows and processes must first be aligned to successfully use the technology – is pharma ready?

“AI is very sexy … And it sounds really good and it's going to be helpful and solve these issues for you. But the reality is about 70% of AI products fail,” ​said Ron Williams, CEO of Business Evolution, during a panel discussion at the SCOPE Summit last week.

Why do so many products fail? Because they start with AI, he said. “And you can’t start with AI; AI is the last step of the process.”

The first step is fixing workflows, said Williams, “If our workflow is broken and we don’t fix it, not only are we moving bad data into AI, we’re going to accelerate the bad process.”

Combining bad data with bad processes is going to yield a “disappointing result,”​ he added. And the successful implementation of the technology is going to be a long road – and as Williams said, AI is not the panacea.

“Breaking down the thought process is the first change that will allow innovation to be leveraged,”​ he added, calling the industry’s behavior “very consistent with the old way of thinking.”

“I need you to engage a different thought process and different framework,”​ said Williams, providing insight from outside the industry.

Offering his thoughts as the head of clinical trial analytics at Bristol-Myers Squibb, Balazs Flink, MD, said that while pharma likes to think it is unique – it is “unique in the way that every other industry is unique.”

Flink said, “We have to constantly challenge ourselves,”​ to meet the need of patients and providers amid a rapidly changing value framework.

Still, the challenge of successfully using AI is not to be diminished. “AI works best in a relatively standardized, stable environment,”​ said Flink. “We are not there yet.”

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us


View more